496 related articles for article (PubMed ID: 21610241)
21. The predictive capacity and additional prognostic power of N-terminal pro-B-type natriuretic peptide in Chinese elderly with chronic heart failure.
Fu S; Xie L; Li D; Ye P; Luo L
Clin Interv Aging; 2015; 10():359-65. PubMed ID: 25670892
[TBL] [Abstract][Full Text] [Related]
22. Chromogranin A and C-terminal endothelin-1 precursor fragment add independent prognostic information to amino-terminal proBNP in patients with acute destabilized heart failure.
Dieplinger B; Gegenhuber A; Struck J; Poelz W; Langsteger W; Haltmayer M; Mueller T
Clin Chim Acta; 2009 Feb; 400(1-2):91-6. PubMed ID: 19000665
[TBL] [Abstract][Full Text] [Related]
23. Copeptin (C-terminal pro arginine-vasopressin) is an independent long-term prognostic marker in heart failure with reduced ejection fraction.
Pozsonyi Z; Förhécz Z; Gombos T; Karádi I; Jánoskuti L; Prohászka Z
Heart Lung Circ; 2015 Apr; 24(4):359-67. PubMed ID: 25618448
[TBL] [Abstract][Full Text] [Related]
24. Increase in N-terminal pro-brain natriuretic peptide levels, renal function and cardiac disease in the oldest old.
Poortvliet R; de Craen A; Gussekloo J; de Ruijter W
Age Ageing; 2015 Sep; 44(5):841-7. PubMed ID: 26209786
[TBL] [Abstract][Full Text] [Related]
25. Copeptin in heart failure: Review and meta-analysis.
Zhong Y; Wang R; Yan L; Lin M; Liu X; You T
Clin Chim Acta; 2017 Dec; 475():36-43. PubMed ID: 28982590
[TBL] [Abstract][Full Text] [Related]
26. C-terminal provasopressin (copeptin) as a prognostic marker after acute non-ST elevation myocardial infarction: Leicester Acute Myocardial Infarction Peptide II (LAMP II) study.
Narayan H; Dhillon OS; Quinn PA; Struck J; Squire IB; Davies JE; Ng LL
Clin Sci (Lond); 2011 Jul; 121(2):79-89. PubMed ID: 21309746
[TBL] [Abstract][Full Text] [Related]
27. N-terminal pro brain natriuretic peptide but not copeptin improves prediction of heart failure over other routine clinical risk parameters in older men with and without cardiovascular disease: population-based study.
Wannamethee SG; Welsh P; Whincup PH; Lennon L; Papacosta O; Sattar N
Eur J Heart Fail; 2014 Jan; 16(1):25-32. PubMed ID: 23901058
[TBL] [Abstract][Full Text] [Related]
28. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study.
Jhund PS; Anand IS; Komajda M; Claggett BL; McKelvie RS; Zile MR; Carson PE; McMurray JJ
Eur J Heart Fail; 2015 Aug; 17(8):809-17. PubMed ID: 25921853
[TBL] [Abstract][Full Text] [Related]
29. Plasma copeptin levels and prediction of outcome in heart failure outpatients: relation to hyponatremia and loop diuretic doses.
Balling L; Kistorp C; Schou M; Egstrup M; Gustafsson I; Goetze JP; Hildebrandt P; Gustafsson F
J Card Fail; 2012 May; 18(5):351-8. PubMed ID: 22555263
[TBL] [Abstract][Full Text] [Related]
30. Can NT-proBNP predict risk of cardiovascular mortality within 10 years? Results from an epidemiological study of elderly patients with symptoms of heart failure.
Alehagen U; Dahlström U
Int J Cardiol; 2009 Apr; 133(2):233-40. PubMed ID: 18407361
[TBL] [Abstract][Full Text] [Related]
31. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure.
de Antonio M; Lupon J; Galan A; Vila J; Urrutia A; Bayes-Genis A
Am Heart J; 2012 May; 163(5):821-8. PubMed ID: 22607860
[TBL] [Abstract][Full Text] [Related]
32. Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial.
Greene SJ; Maggioni AP; Fonarow GC; Solomon SD; Böhm M; Kandra A; Prescott MF; Reimund B; Hua TA; Lesogor A; Zannad F; Gheorghiade M;
Eur J Heart Fail; 2015 Jan; 17(1):98-108. PubMed ID: 25597870
[TBL] [Abstract][Full Text] [Related]
33. Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study.
Cleland JG; Taylor J; Freemantle N; Goode KM; Rigby AS; Tendera M
Eur J Heart Fail; 2012 May; 14(5):487-94. PubMed ID: 22505395
[TBL] [Abstract][Full Text] [Related]
34. The Association of Five-Year Changes in the Levels of N-Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP) with Subsequent Heart Failure and Death in Patients with Stable Coronary Artery Disease: The Heart and Soul Study.
Mishra RK; Judson G; Christenson RH; DeFilippi C; Wu AHB; Whooley MA
Cardiology; 2017; 137(4):201-206. PubMed ID: 28445886
[TBL] [Abstract][Full Text] [Related]
35. The prognostic value of the plasma N-terminal pro-brain natriuretic peptide level on all-cause death and major cardiovascular events in a community-based population.
Zhu Q; Xiao W; Bai Y; Ye P; Luo L; Gao P; Wu H; Bai J
Clin Interv Aging; 2016; 11():245-53. PubMed ID: 27013868
[TBL] [Abstract][Full Text] [Related]
36. Copeptin as a biomarker in heart failure.
Balling L; Gustafsson F
Biomark Med; 2014; 8(6):841-54. PubMed ID: 25224940
[TBL] [Abstract][Full Text] [Related]
37. Hyponatremia, natriuretic peptides, and outcomes in acutely decompensated heart failure: results from the International Collaborative of NT-proBNP Study.
Mohammed AA; van Kimmenade RR; Richards M; Bayes-Genis A; Pinto Y; Moore SA; Januzzi JL
Circ Heart Fail; 2010 May; 3(3):354-61. PubMed ID: 20332419
[TBL] [Abstract][Full Text] [Related]
38. NT-ProBNP reduction percentage during admission for acutely decompensated heart failure predicts long-term cardiovascular mortality.
Bayés-Genís A; Lopez L; Zapico E; Cotes C; Santaló M; Ordonez-Llanos J; Cinca J
J Card Fail; 2005 Jun; 11(5 Suppl):S3-8. PubMed ID: 15948093
[TBL] [Abstract][Full Text] [Related]
39. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure.
Gegenhuber A; Struck J; Dieplinger B; Poelz W; Pacher R; Morgenthaler NG; Bergmann A; Haltmayer M; Mueller T
J Card Fail; 2007 Feb; 13(1):42-9. PubMed ID: 17339002
[TBL] [Abstract][Full Text] [Related]
40. NT-proBNP is increased in differentiated thyroid carcinoma patients and may predict cardiovascular risk.
Klein Hesselink EN; van der Horst-Schrivers ANA; van der Horst ICC; Bakker SJL; Muller Kobold AC; Brouwers AH; de Bock GH; Gietema JA; Dullaart RPF; Links TP; Lefrandt JD
Clin Biochem; 2017 Aug; 50(12):696-702. PubMed ID: 28242284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
